Market Place
Sourcing Support
NeuBase Therapeutics Announces Receipt of Notice from Nasdaq
05 Apr 2024 //
GLOBENEWSWIRE
NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder
08 Sep 2023 //
GLOBENEWSWIRE
NeuBase Therapeutics to Explore Strategic Alternatives
03 Aug 2023 //
GLOBENEWSWIRE
NeuBase Announces Closing of $5 Million Concurrent Registered Direct Offerin
30 Jun 2023 //
GLOBENEWSWIRE
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors
29 Jun 2023 //
GLOBENEWSWIRE
NeuBase Announces $5 Million Concurrent Registered Direct Offering
28 Jun 2023 //
GLOBENEWSWIRE
NeuBase Announces 1-for-20 Reverse Stock Split
14 Jun 2023 //
GLOBENEWSWIRE
NeuBase to Participate in Jefferies Healthcare Conference
24 May 2023 //
GLOBENEWSWIRE
NeuBase Announces Positive Data Supporting the Capabilities of Stealth Editors
22 May 2023 //
GLOBENEWSWIRE
NeuBase Announces Formation of Gene Editing Advisory Board
16 May 2023 //
GLOBENEWSWIRE
NeuBase Reports Business Update and Financial Results for the Q1 of 2023
11 May 2023 //
GLOBENEWSWIRE
NeuBase Therapeutics Selected to Present Two Oral Presentations at ASGCT 2023
02 May 2023 //
GLOBENEWSWIRE
NeuBase Reports Financial Results for the First Quarter of Fiscal Year 2023
14 Feb 2023 //
GLOBENEWSWIRE
NeuBase Therapeutics Reports Business Update and Financial Results forFY2022
21 Dec 2022 //
GLOBENEWSWIRE
NeuBase announces gene editing research pact with 10 Global Healthcare Company
26 Oct 2022 //
PHARMABIZ
NeuBase Announces Gene Editing Research Agreement with Global Healthcare Company
21 Oct 2022 //
GLOBENEWSWIRE
NeuBase lays off 60% of employees as it swaps out antisense focus
17 Oct 2022 //
ENDPTS
NeuBase Announces Strategic Restructuring Focused on Advancing Its Platform
14 Oct 2022 //
GLOBENEWSWIRE
NeuBase Therapeutics Reports Business Update and Financial Results
11 Aug 2022 //
GLOBENEWSWIRE
NeuBase Tx Announces Promotion of Dr. William Mann to President and COO
29 Jun 2022 //
GLOBENEWSWIRE
NeuBase to Participate at the Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
NeuBase Therapeutics Reports Financial Results for Second Quarter of FY 2022
12 May 2022 //
GLOBENEWSWIRE
NeuBase Therapeutics Announces Presentations at the ASGCT
02 May 2022 //
GLOBENEWSWIRE
NeuBase Tx Presents New PC Data at MDA 2022 for DM Type 1 Program, NT-0231.F
13 Mar 2022 //
GLOBENEWSWIRE
NeuBase to Present at Oppenheimer`s 32nd Annual Healthcare Conference
07 Mar 2022 //
GLOBENEWSWIRE
NeuBase Tx to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program
28 Feb 2022 //
GLOBENEWSWIRE
NeuBase Tx Reports Business Update and Financial Results for Q1 Fiscal Year 2022
10 Feb 2022 //
GLOBENEWSWIRE
NeuBase to Present at Oppenheimer Healthcare Life Sciences, MedTech Summit
16 Sep 2021 //
GLOBENEWSWIRE
NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as CTO
14 Sep 2021 //
GLOBENEWSWIRE
